ESTRO 2024 - Abstract Book

S886

Clinical - CNS

ESTRO 2024

Conclusion:

The risk of grade 2+ IH exceeds that of grade 2+ RN in MBM patients undergoing SRS, with or without IO. IH should be considered a critical adverse event following MBM treatments.